EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate (multikinase inhibitor, product name: LENVIMA?, “lenvatinib”) and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN?, “eribulin”) will be given at the American Society of Clinical Oncology (ASCO20 Virtual Scientific Program*), from May 29 to 31, 2020.
* Presentation materials will be made available on demand via ASCO’s website at 8:00 AM on May 29th (ET).
At this year’s meeting, the final results of two studies will be presented on the combination therapy of lenvatinib with the anti-PD-1 antibody KEYTRUDA? (generic name: pembrolizumab, “pembrolizumab”) from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada). One is the oral presentation of the metastatic renal cell carcinoma cohort (Abstract number: 5008) of Study 111 / KEYNOTE-146, and the other is the poster discussion presentation of the first-line therapy for unresectable hepatocellular carcinoma (Abstract number: 4519) in Study 116 / KEYNOTE-524**.
**This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds and investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.